Abstract:Inactivating mutations of von Hippel–Lindau (VHL) are highly prevalent in clear cell renal cell carcinoma (ccRCC). Improved understanding of the vulnerabilities of VHL-deficient ccRCC could lead to improved treatment strategies. The activity of DNA dioxygenase ten-eleven translocation (TET)2 is significantly reduced in multiple cancers by different mechanisms, but its role in ccRCC progression remains unclear. Here, we report that increased expression of TET2, but not TET1 and TET3, is negatively associated with tumor metastasis and advanced tumor stage and is positively associated with good prognosis uniquely in ccRCC among all 33 types of cancer in The Cancer Genome Atlas datasets. TET2 restrained glycolysis and pentose phosphate pathway metabolism in a VHL deficiency–dependent manner, thereby suppressing ccRCC progression. Notably, TET2 and VHL mutations tended to cooccur in ccRCC, providing genetic evidence that they cooperate to inhibit the progression of ccRCC. Mechanistically, TET2 was recruited by transcription factor HNF4α to activate FBP1 expression, which antagonized the function of hypoxia-inducible factor-1/2α (HIF1/2α) in metabolic reprogramming to impede ccRCC growth. Stimulating the TET2-FBP1 axis with vitamin C repressed the growth of VHL-deficient ccRCC with wild-type TET2 and increased the sensitivity to glycolysis inhibitors. Moreover, combined expression levels of the HNF4α–TET2-FBP1 axis served as a biomarker of prognosis in patients with ccRCC. This study reveals a unique function of TET2 in the suppression of tumor metabolism and HIF signaling, and it also provides therapeutic targets, potential drugs, and prognostic markers for the management of ccRCC. Significance: The identification of TET2-mediated inhibition of HIF signaling and tumor metabolic reprogramming provides insights for new therapeutic strategies for VHL-deficient ccRCC.

TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation

TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling

TCTP Increases Stability of Hypoxia‐inducible Factor 1α by Interaction with and Degradation of the Tumour Suppressor VHL

Pvhl Acts As a Downstream Target of E2F1 to Suppress E2F1 Activity.

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Tet1 Facilitates Hypoxia Tolerance By Stabilizing The Hif-Alpha Proteins Independent Of Its Methylcytosine Dioxygenase Activity

Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth

CRL4(VprBP) E3 Ligase Promotes Monoubiquitylation and Chromatin Binding of TET Dioxygenases.

Hypoxia Inactivates the VHL Tumor Suppressor Through PIASy-mediated SUMO Modification.

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

Tet2 Activity is Modulated by Sirt1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome

pVHL regulates protein stability of TCF/LEF transcription factor family via ubiquitin-independent proteasomal degradation

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

TET Enzymes Regulate Skeletal Development Through Increasing Chromatin Accessibility of RUNX2 Target Genes

Hypoxia Switches TET1 from Being Tumor-Suppressive to Oncogenic

RNA m 5 C oxidation by TET2 regulates chromatin state and leukaemogenesis

Methyl-CpG-binding Domain Protein 3-Like 2 (MBD3L2) Promotes Tet2 Enzymatic Activity for Mediating 5mc Oxidation

Tet1 Regulates Dna Replication Through Targeting of Minichromosome Maintenance Genes

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein